APA (7th ed.) Citation

T, Y., N, N., H, G., T, H., S, K., K, F., . . . H, T. (2025). Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: A real-world study. Annals of hematology, 104(10), 5191. https://doi.org/10.1007/s00277-025-06619-0

Chicago Style (17th ed.) Citation

T, Yamada, et al. "Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Therapy in Diffuse Large B-cell Lymphoma in Patients Aged 80 Years or Older: A Real-world Study." Annals of Hematology 104, no. 10 (2025): 5191. https://doi.org/10.1007/s00277-025-06619-0.

MLA (9th ed.) Citation

T, Yamada, et al. "Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Therapy in Diffuse Large B-cell Lymphoma in Patients Aged 80 Years or Older: A Real-world Study." Annals of Hematology, vol. 104, no. 10, 2025, p. 5191, https://doi.org/10.1007/s00277-025-06619-0.